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Abstract
Background: Nonbacterial prostatitis, together with chronic pelvic pain syndrome, accounts for 90–95 % of
prostatitis cases. Anti-inflammatory medications are commonly used to reduce storage/inflammatory symptoms
that can deteriorate quality of life. The purpose of this study was to observe the efficacy and safety of
beclomethasone dipropionate rectal suppositories (Topster®) in inflammations of the lower urinary tract in men.
Methods: Patients underwent diagnostic and therapeutic protocols according to current evidence-based practice.
Efficacy assessments: voiding parameters, perineal pain, International Prostate Symptom Score (IPSS), digital rectal
examination (DRE). Adverse events and patient compliance were recorded throughout the study.
Results: One hundred eighty patients were enrolled, mean age 52 ± 14.97. Most frequent diagnosis: nonbacterial
prostatitis (85 %). All patients completed visits 1 and 2. All patients were treated with beclomethasone dipropionate
(BDP) suppositories, 136/180 also with Serenoa repens (SR) extract. Antibiotics were rarely required.
162/180 patients presented clinically significant improvements and terminated treatment.
Mean change vs. baseline in voiding frequency: −3.55 ± 2.70 n/day in patients taking only BDP and −3.68 ± 2.81 n/day
in those taking both BDP and SR (P<.0001 in both groups). Uroflowmetry improved significantly; change from baseline
3.26 ± 5.35 ml/s in BDP only group and 5.61 ± 7.32 ml/s in BDP + SR group (P = 0.0002 for BDP, P<.0001 for BDP + SR).
Urine stream normal in 35 % of patients at visit 1 and 57.22 % of patients at visit 2. Mean change in perineal pain, on
0–10 VAS, −0.66 ± 2.24 for BDP only group (P = 0.0699) and −1.37 ± 2.40 for BDP + SR group (P<.0001). IPSS increased at
visit 2. No adverse events were reported.
For all parameters, none of the comparisons between groups was found to be statistically significant.
Conclusion: This study confirmed the drug’s good safety profile. We also observed an improvement in the main
storage symptoms and clinical findings associated with lower urinary tract inflammation in patients treated with
beclomethasone dipropionate suppositories.
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Background
Inflammation of the lower urinary tract, especially of the
prostate, commonly affects men of a wide age range,
with detrimental repercussions on quality of life [1–3].
Symptoms include pelvic pain and a variable degree of
voiding and sexual dysfunction [4, 5].
Although prostatitis is historically considered mainly a
bacterial disease, its most common form is chronic
prostatitis/chronic pelvic pain syndrome, accounting for
90–95 % of prostatitis cases [1, 2, 6].
Traditional medical therapy for prostatitis is centered
on treating infection with antimicrobials, although less
than 10 % of prostatitis cases are bacterial, and on allevi-
ating symptoms with NSAIDS, alpha-blockers, 5-Alpha-
Reductase Inhibitors, and phytotherapy [2, 6, 7].
Currently, corticosteroids are not considered “standard
of care” for treating prostatitis. However, in a double-
blinded, randomized, parallel study, 160 patients pre-
senting with chronic nonbacterial prostatitis received
prednisone and levofloxacin or levofloxacin and placebo;
significant differences between the two groups as well as
between pre- and post-treatment (P < 0.01) were found
for total NIH-CPSI score, pain index, voiding index and
quality of life [5]. Currently beclomethasone dipropio-
nate suppositories is a part of the standard practice in
the hospital.
Furthermore, new formulations of corticosteroids have
been developed to limit systemic activity and reduce cor-
ticosteroid adverse events [8–12]. Second-generation
oral or rectal corticosteroids such as beclomethasone di-
propionate have high topical anti-inflammatory efficacy
in the gut and minimal systemic bioavailability due to
low absorption and highly efficient first-pass hepatic in-
activation [10, 11]. A systematic review of rectal therap-
ies for distal forms of ulcerative colitis found that a
greater percentage of patients receiving 5-aminosalicylic
acid or corticosteroid rectal formulations obtained thera-
peutic benefit after treatment compared with placebo
[13]. The overall safety profile of rectal therapies was fa-
vorable and treatment with beclomethasone dipropio-
nate did not increase the incidence of steroid-related
adverse events [9, 10, 12, 13].
The objectives of this study were to collect safety data
and observe the effects of beclomethasone dipropionate
(Topster®, SOFAR S.p.A., Milan, Italy) rectal suppositor-
ies on symptoms associated with lower urinary tract
inflammation.
Methods
This was a prospective, observational, single-center
study performed on outpatients referred to a high-
volume academic teaching hospital in Italy. The study
was approved by the local Ethics Committee and written
informed consent was obtained from all patients.
Male patients presenting with storage/inflammatory
symptoms of the lower urinary tract (pelvic pain, voiding
and sexual dysfunction) were observed as they under-
went diagnostic and therapeutic protocols according to
clinical practice. Subjects affected by coagulation impair-
ments, cardiovascular or pulmonary comorbidities were
excluded from the observation, along with those who
had undergone a prostatic biopsy within the previous
14 days.
Semen and urine cultures were performed at baseline
to determine if the inflammation was triggered by an
infection, and whether an antibiotic was therefore
indicated.
The following parameters were assessed at each visit:
voiding frequency, uroflowmetry, urine stream, perineal
pain, prostate-specific antigen (PSA), International
Prostate Symptom Score (IPSS) [14] and digital rectal
examination (DRE) (evaluation of prostate size, tem-
perature and consistency).
At visit 1, baseline clinical assessments were per-
formed and therapy was prescribed according to current
evidence-based practice [1, 2, 15, 16]. Patients were then
re-evaluated at visit 2, after the end of the treatment
course.
A patient was considered “responder” to therapy fol-
lowing a clinically significant improvement of the evalu-
ated parameters (i.e. voiding frequency, uroflowmetry,
urine stream, perineal pain) and the patient’s impression
of a good clinical outcome.
Drugs prescribed and rationale
Beclomethasone dipropionate (BDP) rectal suppositories
(3 mg, 1 supp. once a day) were prescribed for the relief
of inflammation-related storage symptoms. The duration
of treatment varied depending on the patient’s condi-
tions: 10-day courses were prescribed to patients with
mild symptoms (e.g. perineal pain on a 0–10 VAS be-
tween 4 and 6, voiding frequency less than 10 times a
day) or to those expected not to comply with longer
treatment; 20-day courses in other cases (severe symp-
toms, high compliance expected).
Serenoa repens (SR) 320 mg (1 tab. a day for 60 days)
was suggested as adjuvant treatment for voiding and
storage symptoms due to prostatic hypertrophy and in-
flammation. We used the only formulation registered as
a drug (and not as a dietary supplement) in Italy
(Permixon 320 mg®), as requested by the Ethics commit-
tee due to the current Literature evidence. It was not
prescribed in patients who had already undergone this
treatment with unsatisfactory outcomes.
An antibiotic course was prescribed in case of bacterial
infection (positive seminal fluid and/or urine cultures).
The specific antibiotic was recommended according to
antibiogram results, patient preference regarding route
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of administration and current guidelines for the outpatient
treatment of lower urinary tract infections [15, 16].
A diet (no alcohol, beer or spicy food) and/or hygiene
rules (e.g. avoid cycling/riding, prolonged/interrupted
sexual intercourse, constipation/diarrhea) were also
recommended.
Safety monitoring consisted in gathering all adverse re-
actions occurring during the study.
All statistical tables, figures, listings and analyses were
produced using SAS® for Windows release 9.4 (64-bit) or
later (SAS Institute Inc., Cary, NC, USA). Box plots for
IPSS score, uroflowmetry, urination frequency, PSA and
perineal pain were produced by visit and by type of ther-
apy (BDP suppositories only for patients in group A, or
BDP suppositories plus SR for patients in group B). Dif-
ferences between visit 2 and baseline were analyzed by
means of a paired t-test in case of normal data distribu-
tion, or a non-parametric Wilcoxon signed rank sum
test otherwise. A two independent samples t-test was
performed in order to compare the two treatment
groups if the changes vs. baseline were normally distrib-
uted. Otherwise, the analogous non-parametric test
(Wilcoxon-Mann–Whitney test) was used.
Results
One hundred eighty patients were enrolled in this study
between January and December 2013 and all of them
completed both visit 1 and visit 2. One hundred
thirty-six patients were treated with both BDP and SR
(Group B), whereas 44 were treated with BDP only
(Group A).
Patients averaged 52 years of age (SD 14.9, range 22–
87) and nonbacterial prostatitis was by far the most fre-
quent diagnosis, affecting 89.7 % of patients treated with
BDP + SR (Group B) and 70.4 % of those treated with
BDP (Group A) (Table 1). The mean duration of symp-
toms was 2.7 ± 1.8 months (range 1–12 months) and the
number of previous episodes 1.2 ± 1.2 (range 0–6).
Approximately 26 % of patients had undergone previous
treatment with antibiotics, of which ciprofloxacin, cefix-
ime and levofloxacin were the most commonly prescribed.
Urine and semen cultures at visit 1 were positive in 13
(7.2 %) and 12 (6.6 %) patients respectively.
All 180 patients underwent at least one course of ther-
apy with BDP suppositories. Serenoa repens 320 mg
(saw palmetto extract) was prescribed to 136 patients.
Antibiotics were prescribed to only one patient (Table 2).
The other patients with positive urine or semen cultures
were already taking the proper antibiotic prescribed by
their general practioner.
At visit 2, all patients reported being compliant with
the prescribed therapies and suggestions concerning diet
and lifestyle.
Mean time elapsed between visits was 99.6 ± 38.3 days
(range 27–179 days).
Efficacy results
One hundred sixty-two of the 180 patients treated with
BDP presented clinically significant improvements and
terminated treatment. Further therapeutic interventions
were required for only 18 patients.
The study evidenced noteworthy improvements in void-
ing parameters. Considering voiding frequency, the
changes from baseline were found to be statistically sig-
nificant (P<.0001) in both groups (−3.5 ± 2.7 n/day in pa-
tients taking only BDP suppositories and −3.6 ± 2.8 n/day
in those taking both BDP and SR), whereas the differ-
ence in mean change between the two groups was
not (p-value = 0.8560) (Fig. 1).
Uroflowmetry values also improved considerably, with
mean values increasing of 3.26 ± 5.35 mL/s in the Group
A and 5.6 ± 7.3 mL/s in the Group B. The difference
between the two groups was again not statistically sig-
nificant (P = 0.0638) (Fig. 2).
Uroflowmetry data reported in Table n°3 are also
matched with voided volume and post voided residual
Table 1 Diagnosis
Total Treatment
Group A Group B
(N = 181) (N = 45) (N = 136)
N % N % N %
Diagnosis at Baseline Chlamydial Urethritis 2 1.10 1 2.27 1 0.74
Chronic Nonbacterial Prostatitis 3 1.66 0 0.00 3 2.21
Nonbacterial Prostatitis 154 85.08 31 70.45 122 89.71
Nonbacterial Prostatitis (First episode) 3 1.66 1 2.27 2 1.47
Post Endoscopic Resection Urethritis 11 6.08 7 15.91 4 2.94
Results of pyelonephritis 1 0.55 0 0.00 1 0.74
Urethritis 7 3.87 4 9.09 3 2.21
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(PVR) to assess the improvements from baseline. The
percentage of patients reporting normal urine stream in-
creased significantly, from 43.1 % at baseline to 54.5 %
at visit 2 in Group A patients, and from 32.3 to 58.1 %
in Group B patients.
At visit 2, patients reported feeling less perineal pain,
assessed by means of a Visual Analogue Scale of 0–10.
The t-test for the difference between groups was not
statistically significant although the p-value (0.0787)
suggested a slightly stronger decrease among patients
administered both BDP and SR (Fig. 3).
DREs were performed to evaluate prostate volume,
temperature and consistency. A clear trend was not ap-
parent for size; an enlarged prostate was detected in
50.5 % of the patients at visit 1, and 60.5 % at visit 2. On
the contrary, the number of patients with a warm pros-
tate decreased from 42.7 % of the patients at visit 1 to
5.5 % of the patients at visit 2. Clinical evidence of an in-
flamed prostate at DRE was reported in 83.8 % of the pa-
tients at visit 1, whereas 87.7 % of the patients presented
a normal prostate at visit 2.
The mean change from baseline in IPSS was 2.1 ± 7.9
(P = 0.0767) in Group A patients and 4.7 ± 7.9 (P <.0001)
in Group B patients, which could suggest a worsening of
IPSS score over time, although a temporary rise in score
prior to final improvement is quite common in this
pathology. The difference in the mean changes from
baseline between the two groups was not statistically
Table 2 Prescribed medications
Total Treatment
Group A Group B
(N = 181) (N = 45) (N = 136)
N % N % N %
Visit Drug Dosage 181 - 45 - 136 -
Visit 1 Patients visited - -
Doxycycline 400 1 tab for 7 days 1 0.55 1 2.27 0 0.00
Serenoa repens 320 mg 1 tab for 40 days 30 16.67 0 0.00 30 22.06
1 tab for 60 days 106 58.89 0 0.00 106 77.94
Beclomethasone dipropionate suppositories 1 supp. for 10 days 28 15.56 1 2.27 27 19.85
1 supp. for 20 days 152 84.44 43 97.73 109 80.15
Fig. 1 Voiding frequency. The bottom of each box is the 25th percentile (Q1), the top is the 75th percentile (Q3), and the internal line is the
median. The whiskers indicate variability outside the upper and lower quartiles, i.e. scores outside the middle 50 %. A circle outside of this range
is an outlier, an observation that is distant from others
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significant although a more marked increase of IPSS was
present among those patients who took both treatments
(Fig. 4).
PSA levels remained stable and below 4.0 ng/mL,
dropping slightly from 3.4 ± 3.2 ng/mL (range 0.07–
21 ng/mL) at visit 1 to 3.07 ± 2.35 at visit 2 (range 1.10–
21.00 ng/mL).
Table 3 contains a summary of all the main efficacy re-
sults of the study, comparing the two groups of patients.
No adverse reactions or adverse events were reported.
Discussion
Chronic inflammation plays an important role in the initi-
ation and progression of a wide spectrum of diseases with
Fig. 2 Uroflowmetry. The bottom of each box is the 25th percentile (Q1), the top is the 75th percentile (Q3), and the internal line is the median.
The whiskers indicate variability outside the upper and lower quartiles, i.e. scores outside the middle 50 %. A circle outside of this range is an
outlier, an observation that is distant from others
Fig. 3 Perineal pain. The bottom of each box is the 25th percentile (Q1), the top is the 75th percentile (Q3), and the internal line is the median.
The whiskers indicate variability outside the upper and lower quartiles, i.e. scores outside the middle 50 %. A circle outside of this range is an
outlier, an observation that is distant from others
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prostate involvement [17]. Therefore, anti-inflammatory
medications are commonly used in clinical practice for
the treatment of several prostatic diseases, including non-
bacterial prostatitis. These therapies aim principally at
reducing symptoms caused by inflammation (e.g. pelvic
pain, voiding dysfunction) that can significantly impair a
patient’s quality of life [1, 5, 6].
The vast majority of our patients presenting with
lower urinary tract inflammation were affected with
nonbacterial prostatitis (85 %). This was an expected
result given the high prevalence of this pathological
condition [2, 6, 7]. In fact, nearly 50 % of all men ex-
perience prostatitis-like symptoms at least once dur-
ing their lifetime and 90 % of those have abacterial
prostatitis [2, 6, 7].
The majority of patients (152/180) underwent a 20-
day course of therapy with BDP suppositories because of
the severity of symptoms and the high compliance
expected.
Treatment with Serenoa repens is very common and is
driven by evidence-based practice to treat voiding and
mainly storage symptoms of the lower urinary tract
[18–20]. Its widespread use in clinical practice for the
treatment of voiding symptoms is also described in
several studies [21, 22]. Its beneficial effects are linked
mainly to its pro-apoptotic and anti-proliferative proper-
ties, which are mediated by various mechanisms including
inhibition of 5α-reductase, competition with dihydrotes-
tosterone for binding to its receptor and inhibition of
fibroblast-growth factor.
BDP suppositories were already found to be a safe and
well-tolerated medication in previous studies [10, 11].
One-hundred percent treatment compliance and the ab-
sence of adverse reactions in our study substantiate its
good safety profile also in inflammations of the lower
urinary tract.
The vast majority of patients showed a clinically sig-
nificant improvement of symptoms at visit 2. In fact,
voiding parameters (frequency, uroflowmetry and urine
stream) and perineal pain significantly improved during
the study, likely with a positive effect on patients’ quality
of life and perception of good clinical outcome.
We were not able to define a clear trend of improve-
ment of the parameters evaluated by DRE because of the
non-standardizable nature of the assessment. However,
we did observe a tendency toward normalization in
temperature and consistency of the prostate. As ex-
pected, PSA levels remained stable since it is not a spe-
cific parameter for lower urinary tract inflammation.
In our patients, IPSS increased at visit 2. This was
however expected as it is a consequence of the way IPSS
is intended to be used in common clinical practice [14].
The mean change from baseline was 2.1 ± 7.9 (P = 0.0767)
in patients taking only BDP and 4.7 ± 7.9 (P<.0001) in pa-
tients also taking SR. This may indicate a worsening of
IPSS, especially in patients taking both treatments, al-
though a temporary increase in score prior to final im-
provement is quite common in inflammations of the
lower urinary tract [23]. In fact, IPSS is more accurate for
the evaluation of voiding symptoms, whereas BDP is an
Fig. 4 IPSS score. The bottom of each box is the 25th percentile (Q1), the top is the 75th percentile (Q3), and the internal line is the median. The
whiskers indicate variability outside the upper and lower quartiles, i.e. scores outside the middle 50 %. A circle outside of this range is an outlier,
an observation that is distant from others
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anti-inflammatory medication and is therefore meant to
act mainly on symptoms of the lower urinary tract defined
as storage symptoms [24]. Secondly, IPSS echoes the
patient's symptoms in the last 4 weeks and does not reflect
the 1-day status at visit 2. Therefore, a complete remission
of the lower urinary tract inflammation at visit 2 may not
be related to an evident improvement in IPSS. Moreover,
despite the fact that IPSS is a validated questionnaire, it
reflects the patient's feelings and is surely less objective
than the other tests performed [25]. As a last comment,
we prevented adding bias to this study by not prescribing
any alpha-blockers; this choice was made based on the
evidence that a lower urinary tract inflammatory disease
has to be treated to improve the patients' symptoms [26].
Consequently, IPSS is a tool more suitable for evaluating
the long-term outcome of a medical or surgical treatment
rather than for the first control after a course of therapy
with an anti-inflammatory medication [27].
Given that a significant number of patients took both
BDP and SR, we decided to perform a post-hoc analysis
in order to exclude any confounding results consequent
to the association therapy; none of the comparisons be-
tween groups of all the parameters evaluated (voiding
frequency, uroflowmetry, perineal pain, IPSS and PSA)
were found to be statistically significant. These results
confirm the positive effects of BDP suppositories in the
treatment of lower urinary tract inflammation. As this is
the very first study of its kind, the effectiveness of BDP
in lower urinary tract inflammation should be confirmed
in a randomized, double-blinded, prospective study.
Conclusion
Beclomethasone dipropionate proved to be a safe and
tolerable drug for treating lower urinary tract inflamma-
tions as no adverse events or adverse reactions were re-
ported during the course of the study. All the main
parameters (voiding frequency, uroflowmetry, urine
stream, perineal pain) improved, except for an increase
in IPSS. No significant differences were observed be-
tween patients treated with only beclomethasone dipro-
pionate and those also treated with serenoa repens.
Although randomized, controlled studies are required to
substantiate these findings, our preliminary clinical ob-
servations support the use of beclomethasone dipropio-
nate rectal suppositories in male patients affected by
lower urinary tract inflammation.
Abbreviations
BDP, Beclomethasone dipropionate; DRE, Digital rectal examination; IPSS,
International Prostate Symptom Score; PSA, Prostate Specific Antigen; PVR,
Post voided residual; SR, Serenoa repens.
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Table 3 Summary table
Variable Treatment
Group A Group B
(N = 45) (N = 136)
Age 53.3 ± 15.1 51.8 ± 14.9
IPSS
Baseline value 21.6 ± 7.2 18.3 ± 6.4
Value at visit 2 23.7 ± 6.1 23.1 ± 5.7
Change from baseline 2.1 ± 7.9 4.7 ± 7.9
Test of change from baseline P = 0.0767 P < .0001
Change vs baseline – test between
two groups Two-Sample T-Test
P = 0.0593
Voiding frequency (n/day)
Baseline value 7.7 ± 2.5 7.8 ± 2.1
Value at visit 2 4.2 ± 1.4 4.1 ± 1.9
Change from baseline −3.5 ± 2.7 −3.6 ± 2.8
Test of change from baseline P < .0001 P < .0001
Change vs baseline – test between
two groups Two-Sample T-Test
P = 0.8560
Uroflowmetry (ml/s)
Baseline value 13.1 ± 6.5 11.6 ± 3.8
Value at visit 2 16.4 ± 6.7 17.2 ± 6.5
Change from baseline 3.2 ± 5.3 5.6 ± 7.3
Test of change from baseline P = 0.0002 P < .0001
Change vs baseline – test between
two groups Two-Sample T-Test
P = 0.0638
Voided volume and post voided residual PVR (ml)












Test of change from baseline P = 0.0002 P < .0001
Change vs baseline – test between
two groups Two-Sample T-Test
P = 0.0478
Perineal pain
Baseline value 3.2 ± 1.8 3.8 ± 2.0
Value at visit 2 2.5 ± 1.2 2.4 ± 1.1
Change from baseline −0.6 ± 2.2 −1.3 ± 2.4
Test of change from baseline P = 0.0699 P < .0001
Change vs baseline – test between
two groups Two-Sample T-Test
P = 0.0787
PSA
Baseline value 2.8 ± 2.3 3.6 ± 3.5
Value visit 2 2.9 ± 2.1 3.1 ± 2.4
Change from baseline 0.1 ± 2.5 −0.5 ± 3.7
Test of change from baseline 0.5837 0.5036
Change vs baseline – test between
two groups Two-Sample T-Test
P = 0.3613
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